The golden age of scientific breakthroughs in Alzheimer’s disease diagnosis and treatment is now

This year, the AAIC brought together more than 12,000 researchers, clinicians, healthcare professionals, industry representatives, regulators, and patient advocates from around the globe, making it the largest global meeting dedicated to Alzheimer’s disease and dementia research. 

What we see is that treatments and diagnostics are now developing together.

This year’s meeting in London highlighted how rapidly the Alzheimer’s field is moving from a research-driven era towards one defined by earlier diagnosis, real-world implementation of disease-modifying therapies, and more precise patient stratification. What we see is that treatments and diagnostics are now developing together: as anti-amyloid therapies become available in more markets and next-generation therapeutic approaches advance, the need for scalable, accurate, and clinically useful diagnostic tools has become urgent.

One of the most striking themes at AAIC was the growing emphasis on real-world implementation of disease-modifying therapies. As anti-amyloid treatments enter routine practice, the focus is shifting toward patient selection, monitoring, treatment burden, and long-term outcomes. Presentations from memory clinics and treatment centers highlighted how healthcare systems can integrate these therapies while maintaining safety and access. 

On the treatment side, anti-amyloid therapies continued to shape the clinical treatment landscape. Data and sessions around lecanemab and donanemab focused not only on efficacy and safety, but also on practical questions that will determine how these therapies are adopted in real-world care. For lecanemab, presentations highlighted subcutaneous administration, maintenance dosing, patient and care partner experience, and real-world use in diverse clinical settings. Subcutaneous administration and more flexible maintenance regimens could reduce treatment burden and expand access. For donanemab, new analyses provided further insights into long-term outcomes, safety mitigation, and biomarker effects. The focus on modified titration and corticosteroid pretreatment reflected the field’s ongoing effort to optimize the benefit-risk profile of amyloid-targeting therapies. Together, the lecanemab and donanemab data showed that disease-modifying therapies are now being evaluated beyond pivotal trial endpoints. The discussion has shifted toward durability, patient preferences regarding administration mode, monitoring, and integration into routine care. 

In a study of more than 1,300 patients and 165 physicians, access to blood test results enabled primary care physicians to reach diagnostic accuracy close to that of dementia specialists, around 90%.

Another major theme at AAIC was the accelerating role of blood-based biomarkers in Alzheimer’s diagnosis. New real-world data presented at the congress suggested that blood tests measuring amyloid beta and phosphorylated tau can substantially improve diagnostic accuracy in both specialist and primary care settings. In a study of more than 1,300 patients and 165 physicians, access to blood test results enabled primary care physicians to reach diagnostic accuracy close to that of dementia specialists, around 90%. The findings are important because amyloid PET and cerebrospinal fluid testing remain costly and difficult to access. The data indicated that blood tests could improve referral decisions and reduce diagnostic bottlenecks. 

Multiplex platforms will ultimately support a more personalized approach to treatment selection and monitoring.

Several presentations also reinforced the central role of p-tau217 as one of the most promising blood-based markers of Alzheimer’s pathology. New data from diagnostic programs compared p-tau217 assays with amyloid PET and suggested that such tests may offer strong rule-in performance for identifying Alzheimer’s pathology, including in research settings involving cognitively unimpaired individuals. At the same time, the field is moving beyond single-marker approaches. Multiplex platforms will ultimately support a more personalized approach to treatment selection and monitoring. 

Presentations from companies and academic groups showed growing interest in anti-tau antibodies, tau biomarkers, and therapeutic strategies in which amyloid lowering is combined with interventions targeting tau or other disease mechanisms.

Another important theme at AAIC was the renewed momentum around tau and combination treatments. While amyloid removal has validated disease modification as a therapeutic strategy, tau pathology is closely linked to neurodegeneration and clinical progression. Presentations from companies and academic groups showed growing interest in anti-tau antibodies, tau biomarkers, and therapeutic strategies in which amyloid lowering is combined with interventions targeting tau or other disease mechanisms. Eisai, for example, presented data on etalanetug, an anti-MTBR tau antibody, including studies in the context of background lecanemab treatment. Biogen also presented updates on BIIB080 (diranersen) CELIA phase 2 study, an investigational antisense oligonucleotide designed to reduce production of tau protein. The data showed that they were able to lower tau levels in the brain, which translated to reduced cognitive decline on MMSE and ADAS-COG scales.

Beyond amyloid and tau, AAIC also highlighted technologies designed to improve delivery of biologic therapies across the blood-brain barrier, one of the central challenges in neurodegenerative drug development. Several presentations and company updates pointed to receptor-mediated transport and related delivery platforms as potential enablers of the next generation of Alzheimer’s therapies. Delivery technologies such as our own BrainTransporter, and similar approaches being advanced across the field, could therefore become critical for increasing brain exposure, enabling lower doses, improving efficacy and making it possible to target mechanisms that have historically been difficult to reach.  

The likely future is a precision medicine model in which diagnosis, risk assessment, treatment selection, delivery strategy, and monitoring are integrated across the full disease continuum.

Taken together, the data presented at AAIC 2026 suggest a field entering a more mature and clinically complex phase. The core question is no longer whether Alzheimer’s biology can be measured or modified, but how to use biomarkers, therapies, delivery technologies, and care pathways in a way that benefits the right patients at the right time. Blood-based diagnostics could make earlier and more accurate diagnoses feasible at scale, while anti-amyloid therapies are moving from trial settings into practical implementation. At the same time, tau-targeted therapies, combination regimens, and blood-brain barrier delivery technologies point toward a broader next wave of therapeutic innovation. The likely future is a precision medicine model in which diagnosis, risk assessment, treatment selection, delivery strategy, and monitoring are integrated across the full disease continuum – from preclinical pathology to early symptomatic disease and beyond.